These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 24099749

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.
    Clin Ther; 2015 Dec 01; 37(12):2780-7. PubMed ID: 26565077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM, Keating GM.
    CNS Drugs; 2010 Oct 01; 24(10):883-91. PubMed ID: 20839898
    [Abstract] [Full Text] [Related]

  • 7. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR, Henney HR, Cohen R.
    Ann N Y Acad Sci; 2014 Nov 01; 1329():33-44. PubMed ID: 25154911
    [Abstract] [Full Text] [Related]

  • 8. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.
    Neurology; 2013 Apr 16; 80(16):1509-17. PubMed ID: 23535489
    [Abstract] [Full Text] [Related]

  • 9. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR, MSF204 Investigators.
    Ann Neurol; 2010 Oct 16; 68(4):494-502. PubMed ID: 20976768
    [Abstract] [Full Text] [Related]

  • 10. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI, Sobieraj DM, Marinucci LN.
    Curr Med Res Opin; 2012 Jan 16; 28(1):49-56. PubMed ID: 22073939
    [Abstract] [Full Text] [Related]

  • 11. Long-term effects of dalfampridine in patients with multiple sclerosis.
    Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG.
    J Neurol Sci; 2014 Feb 15; 337(1-2):18-24. PubMed ID: 24290498
    [Abstract] [Full Text] [Related]

  • 12. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L, Rossi Sebastiano D, Aquino D, Torri Clerici V, Brenna G, Moscatelli M, Frangiamore R, Giovannetti AM, Antozzi C, Mantegazza R, Franceschetti S, Bruzzone MG, Erbetta A, Confalonieri P.
    J Neurol Sci; 2016 Sep 15; 368():402-7. PubMed ID: 27538672
    [Abstract] [Full Text] [Related]

  • 13. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J, Blight A.
    Curr Med Res Opin; 2011 Jul 15; 27(7):1415-23. PubMed ID: 21595605
    [Abstract] [Full Text] [Related]

  • 14. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE, Fuller MA.
    Ann Pharmacother; 2012 Jul 15; 46(7-8):1010-5. PubMed ID: 22764324
    [Abstract] [Full Text] [Related]

  • 15. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH, Kreymborg K, Vincent AS.
    Drugs R D; 2013 Sep 15; 13(3):175-81. PubMed ID: 23873597
    [Abstract] [Full Text] [Related]

  • 16. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.
    Mult Scler; 2016 Feb 15; 22(2):212-21. PubMed ID: 25921050
    [Abstract] [Full Text] [Related]

  • 17. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C.
    J Neurol Sci; 2016 Sep 15; 368():318-25. PubMed ID: 27538657
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A.
    Expert Opin Drug Metab Toxicol; 2015 Feb 15; 11(2):295-306. PubMed ID: 25510833
    [Abstract] [Full Text] [Related]

  • 19. Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.
    Triche EW, Ruiz JA, Olson KM, Lo AC.
    Clin Neuropharmacol; 2016 Feb 15; 39(2):73-80. PubMed ID: 26818040
    [Abstract] [Full Text] [Related]

  • 20. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.
    Mult Scler; 2016 Jun 15; 22(7):944-54. PubMed ID: 26447066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.